Reviews/Adhd Pharmacotherapy/Viloxazine and guanfacine as approved non-stimulant alternatives for ADHD
Non Stimulant · ADHD-NONSTIM-02 · v2
The claim has two testable scientific parts: that viloxazine and guanfacine are non-stimulant ADHD treatments, and that each has late-stage randomized trial support. The corpus carries both parts strongly. Viloxazine was tested against placebo in separate large trials in adults [1], adolescents [2] and children [3], each showing a real improvement in ADHD symptoms. Guanfacine was similarly tested in adolescents [5], adults [7], a long-term maintenance study [6] and a pooled analysis of four trials [9], and one paper states plainly that it is a non-stimulant medication [6]. The one part the papers themselves do not contain is proof of FDA approval, which is a regulatory fact that lives outside these study texts, so the panel treated it as an uncontested external gap rather than something the corpus establishes.
Viloxazine extended-release beat placebo on ADHD symptom scales in three independent Phase 3 trials: adults (AISRS -15.5 vs -11.7, p = 0.0040) [1], adolescents (ADHD Rating Scale-5, P = 0.0232 and P = 0.0091) [2], and school-age children (P = 0.0004 and P < 0.0001) [3]. Guanfacine extended-release beat placebo in adolescents (effect size 0.52, p < .001) [5] and Japanese adults (-11.55 vs -7.27, P = .0005) [7], sustained efficacy in a randomised-withdrawal maintenance study (treatment failure 49.3% vs 64.9%, p = 0.006) [6], and showed benefit across a pooled analysis of four Phase 3 trials in 1,084 participants [9]. Paper [6] identifies guanfacine explicitly as a nonstimulant medication for ADHD. Every cited endpoint is an ADHD symptom scale reaching statistical significance for both drugs. The contested point: The evidence and panel do not divide on the science; they divide on completeness. The FDA-approval component of the claim is not carried by any paper text [1]-[10] and rests on external background knowledge, and the viloxazine arm's independence is limited because [1][2][3] all come from the same Nasser et al. development programme.
All 10 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Adhd Pharmacotherapy, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus contains no regulatory document; 'FDA-approved' is not evidenced by any paper text and rests on corpus-external background knowledge, though it is uncontested and true.
All viloxazine Phase 3 trials [1][2][3] and the Phase 2 [4] are the same Nasser et al. development programme, limiting evidential independence within the viloxazine arm to a single sponsor.
Where it remains uncertain. The corpus contains no regulatory document, so the 'FDA-approved' component is external to the paper texts [1]-[10], and all three viloxazine Phase 3 trials [1][2][3] originate from one sponsor programme.
Aleatory
Effect sizes vary across age groups and cohorts (e.g. guanfacine ES 0.52 in adolescents [5] and [7] versus 0.688-0.962 across pooled studies [9]), reflecting genuine sampling variability across trials.
Epistemic
No paper in the corpus reports FDA or any regulatory approval, so the 'FDA-approved' component cannot be confirmed from the provided text [1]-[10].
Inferential
Paper [10] studies children with ASD plus ADHD symptoms and reports oppositional-behaviour outcomes, not the general-ADHD symptom endpoint, so extending it to the general-ADHD approval claim would be an inferential stretch.
The load-bearing papers from a corpus of 10, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Viloxazine Phase 3 RCT support in adults.
“The reduction in AISRS total score was significantly greater in subjects treated with viloxazine ER (-15.5) compared with placebo (-11.7), p = 0.0040.”
Panel auditInternal validity: high · scope of inference: Adults aged 18-65 with ADHD, 6-week treatment.Key limitations: 6-week duration only · abstract does not state FDA-approval status
Viloxazine Phase 3 RCT support in adolescents.
“In the 200-mg/d and 400-mg/d VLX-ER treatment groups, a significant improvement was found in the change from baseline in ADHD Rating Scale-5 Total (P = 0.0232, P = 0.0091)”
Panel auditInternal validity: high · scope of inference: Adolescents aged 12-17 with ADHD, 6-week monotherapy.Key limitations: 6-week duration · abstract does not address FDA approval
Viloxazine Phase 3 RCT support in children.
“Statistically significant improvements in ADHD-RS-5 Total score were observed in both the 100- and 200-mg/day SPN-812 treatment groups compared to placebo at week 1 of treatment, which was maintained through end of study (P = 0.0004 and P < 0.0001).”
Panel auditInternal validity: high · scope of inference: Children aged 6-11 with ADHD, 6-week treatment.Key limitations: 6-week duration · abstract does not address FDA approval
Higher viloxazine doses significantly reduced ADHD-RS-IV total score versus placebo, supporting the drug's efficacy as a non-stimulant.
Panel auditInternal validity: medium · scope of inference: Children aged 6-12 with ADHD, 8-week Phase II dose-finding.Key limitations: Phase II, not Phase III · 100 mg dose not significant · does not support the Phase 3 part of the claim
4 of 10 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Both drugs' non-stimulant status and Phase 3 randomized support are decisively carried by the corpus; only the FDA-approval component is external to it, holding confidence just below ceiling.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Regulatory-approval documentation. The claim's 'FDA-approved' component is not carried by any paper text [1]-[10]; it rests entirely on external background. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Attach the FDA approval records / labels for viloxazine and guanfacine to the evidence set so the regulatory component is corpus-grounded rather than assumed.
Open question: Do the viloxazine Phase 3 efficacy results replicate outside the single Nasser et al. sponsor programme? Why it is still open: Trials [1], [2] and [3] (and Phase 2 [4]) all originate from the same programme, so independence cannot be assessed within the corpus.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19